Brain gene therapy targets Parkinson's at its source
NCT ID NCT07157345
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new treatment called PDR-001 for Parkinson's disease. It uses a harmless virus to deliver a peptide into a specific brain area, aiming to clear toxic protein clumps that cause the disease. The study will enroll 12 people with early Parkinson's to check safety and see if it might slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDR-001 (a peptide delivered via gene therapy to clear α-synuclein protein in the brain)
What this could lead to
If successful, this could lead to a treatment that slows or stops Parkinson's disease progression by targeting its root cause, rather than just easing symptoms.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so safety and effectiveness are not yet proven. The gene therapy approach also carries risks like immune reactions or off-target effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China